By IANS,
Mumbai : Pharma major GlaxoSmithKline (GSK) has bagged a deal to sell Japan based Astellas Pharma Inc’s popular injectible anti-fungal agent Micafungin in India.
Announcing this Monday, GlaxoSmithKline said the deal gives it exclusive market rights for the sale of Micafungin (brand name Mycamine) in India.
Micafungin, belonging to a new class of anti-fungal agents used in the medication of deep seated Candida infections, was initially approved by Japanese Agency in 2002, by the US in 2005 followed by other countries.
SUPPORT TWOCIRCLES
HELP SUPPORT INDEPENDENT AND NON-PROFIT MEDIA. DONATE HERE